Activity of Manogepix and Comparators Against Infrequently Encountered Yeast and Mold Isolates from the SENTRY Surveillance Program (2017-2022)

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2024 Jan 11

PMID 38205999

Authors

Michael Pfaller

Michael Huband

Paul A Bien

Cecilia G Carvalhaes

Abby Klauer

Mariana Castanheira

Affiliations

Soon will be listed here.

Abstract

Manogepix is a potent new antifungal agent targeting the fungal Gwt1 enzyme. Manogepix has previously demonstrated potent activity against clinical isolates of both (except ) and species. This study determined the activity of manogepix and comparators against a large collection of infrequently encountered yeast and molds. Manogepix demonstrated potent activity against infrequently encountered yeasts exhibiting elevated MIC values to other drug classes, including spp. (MIC, 0.008/0.12 mg/L), () (MIC, 0.03/0.06 mg/L), (MIC, 0.016-0.06 mg/L), (MIC, 0.016 mg/L), and (MIC, 0.03/0.12 mg/L). Similarly, manogepix was active against infrequently encountered mold isolates and strains exhibiting elevated MIC/MEC values to echinocandins, azoles, and amphotericin B, including (MEC, 0.004 mg/L), spp. (MEC, 0.016/0.06 mg/L), () species complex (MEC, 0.016/0.03 mg/L), (MEC, 0.03/0.06 mg/L), (MEC, 0.008 mg/L), spp. (MEC, ≤0.008/0.016 mg/L), (MEC, 0.06 mg/L), (MEC range, 0.016-0.12 mg/L), and spp. (MEC, 0.03/0.06 mg/L). Manogepix demonstrated potent activity against a majority of the infrequently encountered yeast and mold isolates tested including strains with elevated MIC/MEC values to other drug classes. Additional clinical development of manogepix (fosmanogepix) in difficult-to-treat, resistant fungal infections is warranted.

Citing Articles

Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management.

Akinosoglou K, Livieratos A, Asimos K, Donders F, Donders G Pharmaceutics. 2025; 16(12.

PMID: 39771534 PMC: 11678211. DOI: 10.3390/pharmaceutics16121555.

Structural insights into the inhibition mechanism of fungal GWT1 by manogepix.

Dai X, Liu X, Li J, Chen H, Yan C, Li Y Nat Commun. 2024; 15(1):9194.

PMID: 39448635 PMC: 11502805. DOI: 10.1038/s41467-024-53512-x.

Antifungal Drug Susceptibility Profile of Isolated from Clinical Samples and Dairy Products.

Zareshahrabadi Z, Khaliji S, Roudbari M, Zomorodian K Can J Infect Dis Med Microbiol. 2024; 2024:6594366.

PMID: 39350797 PMC: 11442036. DOI: 10.1155/2024/6594366.

References

Pappas P, Vazquez J, Oren I, Rahav G, Aoun M, Bulpa P . Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial. J Antimicrob Chemother. 2023; 78(10):2471-2480. PMC: 10545531. DOI: 10.1093/jac/dkad256. View

El Zein S, Hindy J, Kanj S . Invasive Infections: An Emerging Threat to Immunocompromised Patients. Pathogens. 2020; 9(11). PMC: 7694990. DOI: 10.3390/pathogens9110922. View

Arendrup M, Prakash A, Meletiadis J, Sharma C, Chowdhary A . Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values. Antimicrob Agents Chemother. 2017; 61(6). PMC: 5444165. DOI: 10.1128/AAC.00485-17. View

Castanheira M, Collingsworth T, Davis A, Deshpande L, Pfaller M . Isavuconazole nonwildtype Aspergillus fumigatus isolates from a global surveillance study display alterations in multiple genes involved in the ergosterol biosynthesis pathway not previously associated with resistance to other azoles. Mycoses. 2021; 64(10):1279-1290. DOI: 10.1111/myc.13267. View

Vazquez J, Pappas P, Boffard K, Paruk F, Bien P, Tawadrous M . Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris Results from a Phase 2 Trial. Antimicrob Agents Chemother. 2023; 67(5):e0141922. PMC: 10190264. DOI: 10.1128/aac.01419-22. View

Gow N, Johnson C, Berman J, Coste A, Cuomo C, Perlin D . The importance of antimicrobial resistance in medical mycology. Nat Commun. 2022; 13(1):5352. PMC: 9466305. DOI: 10.1038/s41467-022-32249-5. View

Arastehfar A, Lass-Florl C, Garcia-Rubio R, Daneshnia F, Ilkit M, Boekhout T . The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens. J Fungi (Basel). 2020; 6(3). PMC: 7557958. DOI: 10.3390/jof6030138. View

Thornton C . Detection of the 'Big Five' mold killers of humans: Aspergillus, Fusarium, Lomentospora, Scedosporium and Mucormycetes. Adv Appl Microbiol. 2020; 110:1-61. DOI: 10.1016/bs.aambs.2019.10.003. View

Kimura M, Asano-Mori Y, Sakoh T, Abe M, Ueno K, Hoshino Y . Factors Associated with Breakthrough Fungemia Caused by , , or Fusarium Species in Patients with Hematological Disorders. Antimicrob Agents Chemother. 2022; 66(3):e0208121. PMC: 8923220. DOI: 10.1128/AAC.02081-21. View

10.

Pfaller M, Watanabe N, Castanheira M, Messer S, Jones R . Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods. J Antimicrob Chemother. 2011; 66(11):2581-4. DOI: 10.1093/jac/dkr342. View

11.

Pfaller M, Woosley L, Messer S, Jones R, Castanheira M . Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme. Mycopathologia. 2012; 174(4):259-71. DOI: 10.1007/s11046-012-9551-x. View

12.

Arendrup M, Chowdhary A, Jorgensen K, Meletiadis J . Manogepix (APX001A) Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs. Antimicrob Agents Chemother. 2020; 64(10). PMC: 7508601. DOI: 10.1128/AAC.00656-20. View

13.

Wiederhold N, Gibas C . From the Clinical Mycology Laboratory: New Species and Changes in Fungal Taxonomy and Nomenclature. J Fungi (Basel). 2018; 4(4). PMC: 6308937. DOI: 10.3390/jof4040138. View

14.

Rivero-Menendez O, Cuenca-Estrella M, Alastruey-Izquierdo A . In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies. J Antimicrob Chemother. 2019; 74(5):1295-1299. DOI: 10.1093/jac/dkz022. View

15.

Skiada A, Pavleas I, Drogari-Apiranthitou M . Rare fungal infectious agents: a lurking enemy. F1000Res. 2017; 6:1917. PMC: 5664977. DOI: 10.12688/f1000research.11124.1. View

16.

Pfaller M, Huband M, Flamm R, Bien P, Castanheira M . Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019). J Glob Antimicrob Resist. 2021; 26:117-127. DOI: 10.1016/j.jgar.2021.04.012. View

17.

Hoenigl M, Salmanton-Garcia J, Walsh T, Nucci M, Neoh C, Jenks J . Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for.... Lancet Infect Dis. 2021; 21(8):e246-e257. DOI: 10.1016/S1473-3099(20)30784-2. View

18.

Arendrup M, Jorgensen K . Manogepix (APX001A) Displays Potent Activity against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs. Antimicrob Agents Chemother. 2020; 64(7). PMC: 7318001. DOI: 10.1128/AAC.00429-20. View

19.

Cornely O, Ostermann H, Koehler P, Teschner D, Limburg E, Kramer W . Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia. J Antimicrob Chemother. 2023; 78(11):2645-2652. PMC: 10631825. DOI: 10.1093/jac/dkad269. View

20.

Rogers T, Verweij P, Castanheira M, Dannaoui E, White P, Arendrup M . Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications. J Antimicrob Chemother. 2022; 77(8):2053-2073. PMC: 9333407. DOI: 10.1093/jac/dkac161. View